Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. [electronic resource]
Producer: 20100419Description: 248-54 p. digitalISSN:- 1095-6859
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Benzamides
- Carcinosarcoma -- drug therapy
- Disease-Free Survival
- Female
- Humans
- Imatinib Mesylate
- Immunohistochemistry
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Piperazines -- adverse effects
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins c-kit -- biosynthesis
- Pyrimidines -- adverse effects
- Receptor, Platelet-Derived Growth Factor beta -- biosynthesis
- Treatment Outcome
- Uterine Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.